CASP3 and carcinoma: In general, and when compared to non-treated mice, tumor reduction in cisplatin-treatments resulted from a diminished proliferation (Ki67+ cells in Supplementary Fig. S5a, b) and an enhanced cell death (c-casp3+ cells in Supplementary Fig. S5a, c) in the carcinomas.